Angiotensin II induces extracellular matrix metalloproteinase inducer expression via an AT1R dependent pathway in aortic atherosclerotic plaque in apolipoprotein E knockout mice

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 13, Issue 1, 2012, Pages 67-75

  Yang, Li Xia ^a   Yang, Zhi Hua ^a   Guo, Rui Wei ^a   Ye, Jin Shan ^a   Liu, Hong ^a  

^a KUNMING GENERAL HOSPITAL   (China)

Author keywords

Angiotensin II; apolipoprotein E knockout mice; AT1R; extracellular matrix metalloproteinase inducer; valsartan

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APOLIPOPROTEIN E; CD147 ANTIGEN; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIPID DIET; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANGIOTENSIN II; ANIMALS; ANTIGENS, CD147; AORTA; APOLIPOPROTEINS E; GENE EXPRESSION REGULATION; LIPIDS; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; PROTEIN TRANSPORT; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAINING AND LABELING;

EID: 84859939589     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320311423780     Document Type: Article

References (23)

1. Niculescu F and Rus H. The role of complement activation in atherosclerosis. Immunol Res 2004; 30: 73-80. (Pubitemid 38998650)
2. Yoon YW, Kwon HM, Hwang KC, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005; 180: 37-44.
3. Iacono KT, Brown AL, Greene MI and Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007; 83: 283-295. (Pubitemid 350087035)
4. Major TC, Liang L, Lu X, Rosebury W and Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002; 22: 1200-1207. (Pubitemid 34764874)
5. Schmidt R, Bultmann A, Ungerer M, et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006; 113: 834-841.
6. Jiang B, Xu S, Hou X, Pimentel DR and Cohen RA. Angiotensin II differentially regulates interleukin-1-beta-inducible NO synthase (iNOS) and vascular cell adhesion molecule-1 (VCAM-1) expression: role of p38 MAPK. J Biol Chem 2004; 279: 20363-20368. (Pubitemid 38623482)
7. Guo RW, Yang, LX, Wang H, Liu B, Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept 2008; 147: 37-44.
8. Browatzki M, Larsen D, Pfeiffer CA, et al. Angiotensin II stimulates matrix metalloproteinase secretion in human vascular smooth muscle cells via nuclear factor-kappaB and activator protein 1 in a redox-sensitive manner J Vasc Res 2005; 42: 415-423. (Pubitemid 41368960)
9. Chaturvedi N. HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation. Lancet 2000; 355: 246-247. (Pubitemid 30068511)
10. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788. (Pubitemid 37093919)
11. Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 917-921. (Pubitemid 43732172)
12. Johnson JL and Jackson CL. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 2001; 154: 399-406. (Pubitemid 32146612)
13. Xu J, Carretero OA, Shesely EG, et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 2009; 94: 322-329.
14. Y Nakashima AP, EW Raines, JL Breslow and R Ross. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 1994; 14: 133-140.
15. Johnson J, Carson K, Williams H, et al. Plaque rupture after short periods of fat feeding in the apolipoproteine-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005; 111: 1422-1430. (Pubitemid 40396809)
16. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G and Schwartz SM. Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 2000; 20: 2587-2592 .
17. Weiss D and Taylor WR. Deoxycorticosterone acetate salt hypertension in apolipoprotein E-/- mice results in accelerated atherosclerosis: the role of angiotensin II. Hypertension 2008; 51: 218-224.
18. Zhu W, Khachi S, Hao Q, et al. Upregulation of EMMPRIN after permanent focal cerebral ischemia. Neurochem Int 2008; 52: 1086-1091.
19. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37: 235-239. (Pubitemid 43732079)
20. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003. (Pubitemid 34286536)
21. Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431-1439. (Pubitemid 46635780)
22. Ruiz-Ortega M, Lorenzo O, Ruperez M, Blanco J and Egido J. Systemic infusion of angiotensin II into normal rats activates nuclear factor-kappaB and AP-1 in the kidney: role of AT(1) and AT(2) receptors. Am J Pathol 2001; 158: 1743-1756. (Pubitemid 32422939)
23. Yang LX, Liu H, Guo RW, et al. Angiotensin II induces EMMPRIN expression in THP-1 macrophages via the NF-kappaB pathway. Regul Pept 163: 88-95.